Application of mesenchymal stem cells as a vehicle to deliver replication-competent adenovirus for treating malignant glioma.
- Author:
Cui HAI
1
;
Yong-Min JIN
;
Wen-Biao JIN
;
Zhe-Zhu HAN
;
Mei-Nv CUI
;
Xue-Zhe PIAO
;
Xiong-Hu SHEN
;
Song-Nan ZHANG
;
Hong-Hua SUN
Author Information
- Publication Type:Journal Article
- MeSH: Adenoviridae; Animals; Brain Neoplasms; pathology; therapy; Cell Line, Tumor; Genetic Vectors; Glioma; pathology; therapy; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oncolytic Virotherapy; Random Allocation; Virus Replication; Xenograft Model Antitumor Assays
- From:Chinese Journal of Cancer 2012;31(5):233-240
- CountryChina
- Language:English
- Abstract: Although gene therapy was regarded as a promising approach for glioma treatment, its therapeutic efficacy was often disappointing because of the lack of efficient drug delivery systems. Mesenchymal stem cells(MSCs) have been reported to have a tropism for brain tumors and thus could be used as delivery vehicles for glioma therapy. Therefore, in this study, we attempted to treat glioma by using MSCs as a vehicle for delivering replication-competent adenovirus. We firstly compared the infectivity of type 3, type 5, and type 35 fiber-modified adenoviruses in MSCs. We also determined suitable adenovirus titer in vitro and then used this titer to analyze the ability of MSCs to deliver replication-competent adenovirus into glioma in vivo. Our results indicated that type 35 fiber-modified adenovirus showed higher infectivity than did naked type 3 or type 5 fiber-modified adenovirus. MSCs carrying replication-competent adenovirus significantly inhibited tumor growth in vivo compared with other control groups. In conclusion, MSCs are an effective vehicle that can successfully transport replication-competent adenovirus into glioma, making it a potential therapeutic strategy for treating malignant glioma.
